After cancer treatment in childhood or young adulthood, follow-up is planned around the treatment a person had. Each survivor should have a written summary of every medicine with its total dose, every radiotherapy area and every operation, and from it a personal plan of checks, such as heart scans, breast screening or hearing tests. The plan should carry on for life, under a survivorship service.
The COG Long-Term Follow-Up Guidelines (Version 6.0, October 2023; 165 exposure sections and 45 patient Health Links) are the most complete exposure-based guideline. They apply from two or more years after the end of treatment to survivors with no symptoms, and work in three moves: obtain the cancer treatment summary (agents, cumulative anthracycline dose in doxorubicin equivalents, radiation fields, with the total dose for the fields where COG still uses one, surgery, transplant and chronic graft-versus-host disease status); compile the sections that apply; and build an individual screening plan. By COG's own count 68 per cent of sections rest mainly on history and examination, 27 per cent include periodic tests and 5 per cent recommend no screening. COG scores each section by expert consensus (1, 2A, 2B) and states that no randomised trial of screening exists in this population. The IGHG harmonises individual topics and grades both the evidence and the strength of each recommendation: cardiomyopathy (2022), breast cancer (2020 and 2025), thyroid cancer (2018), ototoxicity (2019), premature ovarian insufficiency (2016) and male gonadotoxicity (2017) are summarised in the steps. In Europe the PanCareFollowUp recommendations (2021) combine the IGHG guidelines with 25 pragmatic recommendations for topics IGHG has not yet covered, and PanCareSurFup (2019) recommends that risk-adapted follow-up under a survivorship expert service be available to every survivor throughout life, starting no later than 5 years after treatment or 5 years from diagnosis, depending on the health system. Tools that turn a treatment record into a personal plan are Passport for Care (COG) and the European Survivorship Passport.
Where the sources differ: COG examines the thyroid by hand every year after radiation to the head or brain, neck or spine (cervical or whole) or total body irradiation, while IGHG makes thyroid cancer surveillance a shared decision between palpation every 1 to 2 years, ultrasound every 3 to 5 years, or no surveillance; for breast screening IGHG recommends surveillance from 10 Gy or more to the chest, while COG Version 6.0 lists radiation to the chest or axilla or total body irradiation without a minimum dose; COG counts radiation to the chest, abdomen, spine (thoracic or whole) and total body irradiation as radiation with potential impact to the heart, where IGHG speaks of chest-directed radiotherapy; SIGN 132 (2013) and the UK aftercare pathways sort survivors into three levels of follow-up intensity, which COG and IGHG do not. This page explains how follow-up is organised; a survivor's own long-term follow-up team decides the plan, and their plan comes first.
Why: COG expects that, as its guidelines are updated, more detail about past treatment may be needed to work out the right checks, so it asks for everything to be recorded, including medicines its guidelines do not yet cover. PanCareSurFup recommends that the summary and care plan be given at the end of treatment.
“Therefore, we strongly advise that a comprehensive treatment summary be prepared for each childhood cancer survivor, including a record of all therapeutic exposures with applicable dates, details of administration, and cumulative doses of all agents, including those not currently addressed by these guidelines.”
Why: SIGN wants survivors, their carers and every professional who meets them to know the diagnosis and treatment, so that all can watch for signs of problems.
“At the end of a course of cancer treatment, patients, their parents or carers and general practitioners should be given a summary of the treatment and a list of signs of late effects to look out for.”
Scottish Intercollegiate Guidelines Network 2013 · good practice point
Why: COG's guidelines cover late effects of treatment and say plainly that they do not cover follow-up of the original cancer. Other bodies set other starting points: PanCareSurFup says long-term follow-up should start no later than 5 years after treatment or 5 years from diagnosis, depending on the health system.
“These guidelines are intended for use beginning two or more years following the completion of cancer therapy, and provide a framework for ongoing late effects monitoring in childhood cancer survivors; however, these guidelines are not intended to provide guidance for follow-up of the pediatric cancer survivor’s primary disease.”
Why: COG organises its recommendations by the treatment received, so the plan is built from the treatment and then adjusted for the person's risk factors, health, habits and wishes.
“Review all guideline sections generated in the list above, and develop a plan for screening the individual survivor, taking into consideration the survivor’s relevant risk factors, current health, co-morbidities, health-related behaviors and preferences.”
Why: COG says the only version available is written for healthcare professionals, and strongly encourages survivors who read it to do so with a knowledgeable professional, to keep the recommendations in perspective and avoid over-testing.
“This is important in order to put the recommendations in perspective, avoid over-testing, address potential anxieties, and provide a comprehensive evaluation of the survivor’s health status.”
Why: By COG's count 68 per cent of its 165 sections rest mainly on history and examination, 27 per cent include periodic tests and 5 per cent recommend no screening.
“Importantly, the recommended periodic screening underscores the use of a thorough history and physical examination (H&P) as the primary assessment for cancer-related treatment effects.”
Why: COG lists problems with education, work, relationships and independent living, and mental health disorders, as possible late effects of any cancer experience, and names psychology, social work and school liaison as sources of help. The score of 1 is for its section on psychosocial effects; the section on mental health disorders is scored 2A.
“Psychological consultation in patients with emotional difficulties related to cancer experience, including physical deformities or chronic disabilities.”
Children's Oncology Group 2023 · SCORE = 1
Why: IGHG asks survivors and clinicians to be aware of the risk of cardiomyopathy (weakened heart muscle) after these treatments. It recommends scans at high risk, calls them reasonable at moderate risk and does not recommend them at low risk; the linked heart protocol gives the dose bands.
“Cardiomyopathy surveillance is recommended for high-risk CAYA cancer survivors to begin no later than 2 years after completion of cardiotoxic therapy and continued every 2 years thereafter (moderate-quality evidence, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · moderate-quality evidence, strong recommendation
Why: IGHG states an increased risk of breast cancer after this much radiation to the chest, and recommends surveillance beyond the national screening programme. COG gives the same starting point and tests but lists radiation to the chest or axilla or total body irradiation without a minimum dose.
“Initiation of breast cancer surveillance is recommended at age 25 years or ≥8 years from radiation (whichever occurs last) (high-quality evidence, strong recommendation).”
IGHG 2025 · high-quality evidence, strong recommendation
Why: Most thyroid cancers found this way are curable either way, and screening also finds many harmless lumps that lead to biopsies, so the choice is the survivor's.
“It is recommended that at-risk survivors (i.e., those treated with radiation therapy that includes the thyroid gland) (level A evidence) should be counseled about options for differentiated thyroid carcinoma surveillance.”
IGHG with the PanCareSurFup Consortium 2018 · level A evidence
Why: IGHG asks survivors and clinicians to be aware of the risk of hearing loss after these treatments. For those found to have a loss, COG lists ongoing audiology follow-up, speech and language therapy and help at school.
“Referral to an audiologist or auditory clinic is recommended for any survivor who has symptoms suggesting hearing loss or abnormal audiological test results showing a loss of more than 15 dB absolute threshold level (1000–8000 Hz) (expert opinion*).”
IGHG with the PanCare Consortium 2019 · expert opinion
Why: These treatments can cause the ovaries to stop working early; finding it allows hormone replacement and timely advice about fertility.
“Monitoring of growth (height) and pubertal development and progression (Tanner stage) is recommended for pre-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries (expert opinion and no literature search).”
IGHG with the PanCareSurFup Consortium 2016 · expert opinion and no literature search
Why: IGHG recommends counselling about the risk to sperm production and what it means for future fertility, and testing only when the survivor asks for it after discussion or wants to father a child in the foreseeable future.
“Surveillance for impaired spermatogenesis should be performed only at the request of the survivor after informed discussion or when paternity is desired in the foreseeable future (expert opinion).”
IGHG with the PanCareSurFup Consortium 2017 · expert opinion
Why: COG lists colorectal cancer as a possible late effect of radiation to these areas. Its options are colonoscopy every 5 years or a multitarget stool DNA test every 3 years, with a positive stool test followed by colonoscopy.
“Beginning 5 years after radiation or at age 30 years (whichever occurs last)”
Children's Oncology Group 2023 · SCORE = 2A
Why: SIGN says a subsequent cancer may occur at any site, asks GPs to promote national screening programmes, and says patients should report new symptoms promptly so that assessment and treatment are not delayed.
“Healthcare professionals should be aware that survivors of childhood cancer are at particular and lifelong increased risk of developing a subsequent primary cancer and that this may occur at any site on the body.”
Why: SIGN notes that these patients often have a large number and variety of health professionals looking after them, and sees continuity of care as one role of the key worker.
“Each survivor of childhood cancer should have access to an appropriate designated key worker to coordinate care.”
Scottish Intercollegiate Guidelines Network 2013 · good practice point
Why: SIGN says later medical encounters must be informed by a full medical history, especially as the child becomes an adult. PanCareSurFup makes a strong recommendation that the survivorship centre provide a plan for the move from paediatric to adult health services, and the PanCare transition paper (abstract) says many centres have no formal transition programme.
“It should be recognised that teenagers may not want to be seen by paediatric services and that adult services may not be appropriate to follow up survivors of childhood cancers.”
Why: SIGN notes that late effects may not present for many years or decades after treatment, and PanCareSurFup recommends that follow-up be available throughout life.
“We recommend that risk-adapted LTFU care provided under the guidance of a cancer survivorship expert service or cancer centre should be available and accessible for all CAYA cancer survivors throughout their lifespan.”
PanCareSurFup, Journal of Cancer Survivorship 2019 · strong recommendation, low level evidence and expert opinion
Why: PanCareSurFup notes that as survivors grow older they need to take more responsibility for managing their own health.
“To improve health outcomes and quality of survivorship of current and future survivors, continued age-adapted education of survivors about the cancer, its treatment, risk of late effects, importance of health behaviours, and necessity of LTFU is important along the cancer and survivorship trajectory.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Two bodies define current best practice and they are complementary. The COG Long-Term Follow-Up Guidelines, Version 6.0 (October 2023), cover every exposure in one document, updated at least every 5 years, with each section scored by expert consensus; COG says plainly that they are not conventional evidence-based guidelines, because no randomised trial of screening exists in this population. The IGHG guidelines cover fewer topics but grade both the evidence and the strength of each recommendation. COG says one aim of Version 6.0 was to align its screening recommendations better with those of the IGHG, and its review says that, in concordance with the IGHG cardiomyopathy guideline, it no longer recommends screening heart scans for the low-risk group. In Europe, PanCareFollowUp (2021) joins the IGHG guidelines to 25 pragmatic recommendations for topics not yet harmonised, and PanCareSurFup (2019) makes strong recommendations, on low-level evidence and expert opinion, that risk-adapted follow-up under a survivorship expert service be available for life. All agree on the method: a complete treatment summary, a plan derived from exposures, history and examination as the core, and follow-up that continues into adulthood. They differ on particular items. When to start: COG's guidelines are for use from two or more years after treatment; PanCareSurFup says long-term follow-up should start no later than 5 years after treatment or 5 years from diagnosis, depending on the health system. Thyroid after radiation that included the gland: COG schedules a yearly thyroid examination; IGHG recommends counselling and a shared decision between palpation every 1 to 2 years, ultrasound every 3 to 5 years, or no surveillance. Breast: both start yearly mammography and MRI at age 25 or 8 years after chest radiation, whichever is later; IGHG recommends this from 10 Gy or more, calls it reasonable after upper abdominal radiation that exposed breast tissue at a young age and, since 2025, calls surveillance reasonable after 200 mg/m² or more of doxorubicin without chest radiation (from age 30 or 8 years after exposure, at the frequency of national or local guidelines for moderate-risk individuals), and names 60 as the age to which annual surveillance is recommended, while COG lists radiation to the chest or axilla or total body irradiation without a minimum dose (it names 10 Gy or more as raising the risk), adds a clinical breast examination yearly from puberty and six-monthly from 25, and says the upper age limit has not been established. Hearing: the two give the same intervals (yearly to age 5, every 2 years from 6 to 12, then every 5 years), COG after cisplatin, myeloablative carboplatin or 30 Gy or more to the head or brain. Organisation: SIGN 132 and the UK aftercare pathways sort survivors into three levels of follow-up intensity; the COG and IGHG documents read here set the content of surveillance and do not prescribe a model of care, and PanCareSurFup says the model should be chosen with the survivor and will depend on the health system.
Children's Oncology Group 2023 · JAMA Oncology 2025 · International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · IGHG 2025 · IGHG with the PanCareSurFup Consortium 2018 · IGHG with the PanCare Consortium 2019 · PanCareFollowUp Recommendations Working Group, European Journal of Cancer 2021 · PanCareSurFup, Journal of Cancer Survivorship 2019 · Scottish Intercollegiate Guidelines Network 2013 · Children's Cancer and Leukaemia Group (CCLG), a UK charity and professional association 2026
Where it differs: A web tool in which the clinic enters the treatment and receives the COG recommendations that apply to that survivor, instead of working through the full guideline by hand. COG describes it as "a web-based interface, known as “Passport for Care,” that generates individualized exposure-based recommendations from these guidelines in a clinician-focused format".
Evidence: COG's preface names clinicians' limited time and the effort of finding the relevant recommendations as barriers to the guideline's use, and says the tool is free to COG member institutions. No outcome study of the tool was read.
Where it differs: An electronic document given to each survivor, translatable into European languages, holding the treatment history and screening recommendations generated automatically from the IGHG and PanCareSurFup guidelines, which the treating doctor can adjust. The developers describe "personalised follow-up and screening recommendations based on guidelines published by the International Guidelines Harmonization Group and PanCareSurFup."
Evidence: Haupt 2018 (abstract): developed by PanCare and SIOP Europe paediatric oncologists with survivors' and parents' organisations; a data schema of up to 168 variables; tested at one Italian centre, where the abstract reports positive feedback. The abstract estimates 300,000 to 500,000 childhood cancer survivors in Europe. Later implementation studies exist and were not read.
Where it differs: Uses the IGHG guidelines where they exist and adds 25 harmonised recommendations for topics IGHG had not yet addressed, sorted by what each requires: awareness only (6), awareness with history or examination (9), or additional surveillance tests (10).
Evidence: Developed by 23 late effects specialists, researchers and survivor representatives from nine countries by what the authors call a pragmatic methodology, "in anticipation of evidence-based IGHG guidelines", with an external consultation of 18 experts from 14 countries. Read as an abstract only, so the individual recommendations are not given here.
PanCareFollowUp Recommendations Working Group, European Journal of Cancer 2021
Where it differs: Five or more years from treatment, survivors are placed in one of three levels: level 1, surgery alone or low-risk chemotherapy, followed by post or telephone every 1 to 2 years; level 2, chemotherapy or cranial irradiation of 24 Gy or less, followed by a nurse or in primary care every 1 to 2 years; level 3, radiotherapy other than low-dose cranial irradiation, megatherapy or bone marrow transplant, followed yearly in a medically supervised clinic. For level 3 the text says "They should be seen in a medically supervised long term follow up clinic three to four times a year until final height is achieved and at least annually thereafter."
Evidence: Described by SIGN as possible levels of follow up, not a graded recommendation. SIGN notes that nurse-led or primary care-led follow-up "may miss some individual problems", giving early puberty after low-dose cranial irradiation as an example. The guideline dates from 2013 and SIGN's page says some recommendations may be out of date.
Where it differs: CCLG publishes a paediatric aftercare pathway and two teenage and young adult aftercare pathways, one for levels 1 and 2 and one for level 3 complex care, as downloadable diagrams. The page says the initiative "was created to offer each survivor a high-quality, personalised aftercare package enabling them to reach their full potential in life."
Evidence: A public page of a charity and professional association, read as a summary; the pathway diagrams themselves were not read, and no evidence grading is given. The page states there are over 45,000 survivors of children's and young people's cancer in the United Kingdom.
Children's Cancer and Leukaemia Group (CCLG), a UK charity and professional association 2026
Where it differs: COG section 67 (radiation to the head or brain, neck or spine, or total body irradiation) lists a thyroid examination every year, with ultrasound for a lump that can be felt. IGHG asks the clinician to explain the options first: "If periodic thyroid palpation is chosen as the screening modality it may be reasonable to repeat surveillance for differentiated thyroid carcinoma every 1-2 years (expert opinion; weak recommendation)." With ultrasound it may be reasonable to repeat every 3 to 5 years if the first is normal. IGHG calls it reasonable to start either kind of surveillance 5 years after the radiotherapy.
Evidence: IGHG sets out both sides: palpation has low sensitivity (17 to 43 per cent) and high specificity (96 to 100 per cent) for a nodule; ultrasound has high sensitivity and specificity for nodules but poor ability to tell a cancer from a harmless nodule, and "There are no randomized studies that demonstrate a clear benefit of DTC surveillance." COG scores its section 1.
Children's Oncology Group 2023 · IGHG with the PanCareSurFup Consortium 2018
| Recommendation | Grade, as printed | Source |
|---|---|---|
| COG: what a score of 1 means “All “Category 1” recommendations reflect uniform consensus among the reviewers.” | Category 1 | Children's Oncology Group 2023 |
| COG: the guidelines rest on expert consensus because no randomised trials of screening exist “This is due to the fact that there are no randomized clinical trials (and none forthcoming in the foreseeable future) on which to base recommendations for periodic screening evaluations in this population; therefore, the guidelines should not be misconstrued as representing conventional “evidence-based clinical practice guidelines” or “standards of care”.” | statement in the preface (not a graded recommendation) | Children's Oncology Group 2023 |
| COG: possible harms of following the guidelines “Potential harms of guideline implementation include increased patient anxiety related to enhanced awareness of possible complications, as well as the potential for false-positive screening evaluations, leading to unnecessary further workup.” | statement in the preface (not a graded recommendation) | Children's Oncology Group 2023 |
| Annual breast surveillance to at least age 60 after 10 Gy or more of chest radiation “Annual breast cancer surveillance is recommended for at least up to 60 years of age (high-quality evidence, strong recommendation).” | high-quality evidence, strong recommendation | IGHG 2025 |
| Mammography and breast MRI as the surveillance tests after chest or upper abdominal radiation “Mammography and breast MRI are recommended for breast cancer surveillance (high- to moderate-quality evidence, strong recommendation).” | high- to moderate-quality evidence, strong recommendation | IGHG 2025 |
| COG: no upper age limit for breast surveillance has been set “The upper age limit at which mammography and breast MRI should be used for breast cancer surveillance has not been established.” | SCORE = 1 | Children's Oncology Group 2023 |
| Thyroid surveillance may start 5 years after radiotherapy that included the thyroid “It is reasonable to commence surveillance for differentiated thyroid carcinoma 5 years after radiation therapy that includes the thyroid gland or therapeutic 131I-MIBG (level B evidence).” | level B evidence | IGHG with the PanCareSurFup Consortium 2018 |
| Thyroid ultrasound every 3 to 5 years if chosen and the first is normal “If thyroid ultrasonography is chosen as screening modality, it may be reasonable to repeat surveillance for differentiated thyroid carcinoma every 3-5 years if there are no abnormalities found initially (expert opinion).” | expert opinion | IGHG with the PanCareSurFup Consortium 2018 |
| Pure tone audiometry at 1000 to 8000 Hz from age 6, with high-frequency testing where available “Pure tone conventional audiometry testing is recommended for survivors ≥6 years of age at 1000–8000 Hz, and additional testing with high frequency audiometry at >8000 Hz is recommended whenever equipment is available (evidence-based guidelines and expert opinion).” | evidence-based guidelines and expert opinion | IGHG with the PanCare Consortium 2019 |
| Anti-Müllerian hormone is not the primary test for early ovarian failure “AMH is not recommended as the primary surveillance modality for evaluation of premature ovarian insufficiency in survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries† who desire assessment about potential future fertility (expert opinion and no studies).” | expert opinion and no studies | IGHG with the PanCareSurFup Consortium 2016 |
| Semen analysis as the primary test of sperm production for men who want to know “semen analysis is recommended as the gold standard primary surveillance modality for evaluation of spermatogenesis (expert opinion).” | expert opinion | IGHG with the PanCareSurFup Consortium 2017 |
| COG: colonoscopy is the reference test for bowel screening after radiation, with stool DNA testing as an alternative “Colonoscopy is considered the gold standard for colorectal cancer screening in high-risk populations; however, recognizing that not all survivors are willing or able to undergo colonoscopy, multitarget stool DNA testing is deemed a reasonable alternative.” | SCORE = 2A | Children's Oncology Group 2023 |
| PanCareSurFup: strength and evidence of its recommendations on organising follow-up “We provide strong recommendations based on low level evidence and expert opinions, regarding organization of LTFU care, personnel involved in LTFU care, components of LTFU care and start of LTFU care.” | strong recommendations based on low level evidence and expert opinions | PanCareSurFup, Journal of Cancer Survivorship 2019 |
| SIGN: lifelong follow-up as current best practice “Lifelong follow up of survivors is recommended as current best practice (see section 11) and this will necessitate multidisciplinary collaboration between patients and their families, oncologists and other health professionals including those in primary care” | statement in the introduction (not a graded recommendation) | Scottish Intercollegiate Guidelines Network 2013 |
Shares Survivorship care plans generated automatically from the treatment record, Long-term follow-up in the United Kingdom: what a survivor is actually offered, The handover from children's to adult services, where follow-up falls away, The heart after anthracyclines and chest radiotherapy in childhood.
Shares Survivorship care plans generated automatically from the treatment record, The handover from children's to adult services, where follow-up falls away, International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines.
Shares Survivorship care plans generated automatically from the treatment record, End of treatment: treatment summary, survivorship care plan and handover to primary care, The handover from children's to adult services, where follow-up falls away, Fragmented care and guideline gaps.
Shares International Guideline Harmonization Group for late effects of childhood cancer, The heart after anthracyclines and chest radiotherapy in childhood, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age.
Shares Fertility preservation for children and young people before cancer treatment, PanCareSurFup and the European survivor cohorts, International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines.
Shares Hearing protection for children receiving cisplatin, International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age.
Shares International Guideline Harmonization Group for late effects of childhood cancer, Second cancers after childhood cancer: the risk by treatment, and why it is falling, The Children's Oncology Group Long-Term Follow-Up Guidelines, Survivorship care and late-effects surveillance.
Shares Fertility preservation for children and young people before cancer treatment, PanCareSurFup and the European survivor cohorts, International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines.